MET and hepatocellular carcinoma: Since both HGF and MET are significantly elevated in HCC patients, and such elevations suggest poorer prognoses 3, 6, 39, 40, it is essential to further investigate the underlying mechanism of MET and its suppressors for better understanding of HGF/MET signaling in order to develop effective approach for maximize efficacy of anti-HGF/MET treatment in HCC.